Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force “Dermatology for Cancer Patients” and pharmacovigilance analysis
Breast Cancer Research and Treatment · 2026
DOI: 10.1007/s10549-026-08090-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Ioannis-Alexios Koumprentziotis und 15 weiteren Autor:innen. Beteiligte Einrichtung: First Dermatology Department, "A.Sygros" Hospital for Skin Diseases, National and Kapodistrian University of Athens Medical School, Athens, Greece. g…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Camptothecin, Breast Neoplasms, Immunoconjugates. Die Arbeit nennt 24 Literaturangaben.
Themen: Onkologische Pflege, Patientensicherheit
Abstract (Originalsprache)
PURPOSE: Sacituzumab govitecan (SG) is an antibody-drug conjugate approved across multiple metastatic breast cancer settings. Although hematologic and gastrointestinal toxicities dominate its safety profile, dermatologic adverse events (dAEs) remain poorly characterized, despite the physiological expression of Trop-2 in epidermal keratinocytes. We aimed to comprehensively characterize the spectrum, severity, time to onset, and oncologic impact of SG-associated dAEs across real-world and pharmacovigilance data sources. METHODS: An international retrospective cohort study was conducted within the EADV Task Force "Dermatology for Cancer Patients" (n = 56 breast cancer patients). Findings were triangulated with disproportionality analyses of the WHO Global Pharmacovigilance database (VigiBase®; n = 696 cases) and the French Pharmacovigilance Database (FPVD; n = 46 cases), alongside a literature review of SG clinical trials reporting dAEs. RESULTS: Across all data sources, alopecia was the most frequently reported dAE (EADV cohort: 41.1%; FPVD: 52.2%; VigiBase®: 67.6%), followed by stomatitis/mucositis, pruritus, xerosis, and maculopapular rash. In the EADV cohort, 13 distinct dAE types were identified; median time to first dAE was 56 days, and 96.4% of events were grade 1-2. Treatment discontinuation attributable to dAEs occurred in only 3.6% of patients. VigiBase® disproportionality analysis identified significant reporting signals for alopecia (IC 3.3 [3.09; 3.53]), infusion-related reactions (IC 1.9 [1.07; 2.55]), and stomatitis (IC 1.6 [0.86; 2.30]). Preliminary signals of cutaneous infections were observed but did not consistently meet the threshold for statistical significance. CONCLUSION: SG-associated dAEs are predominantly low-grade and infrequently precipitate treatment discontinuation. Pharmacovigilance data raises a potential signal for cutaneous infections that warrants further investigation. As SG increasingly enters combination regimens, structured dermatologic monitoring and prospective characterization of dAEs are essential to guide oncodermatologic management and protect oncological outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Dermatology Department, "A.Sygros" Hospital for Skin Diseases, National and Kapodistrian University of Athens Medical School, Athens, Greece. giannhskmpr@gmail.com.
- Dermatology Department, Skin Unit, Royal Marsden NHS Foundation Trust, London, UK.
- Department of Clinical Pharmacology, Université Côte d'Azur, University Hospital Centre of Nice, Nice, France.
- Laboratory of Molecular Physio Medicine (LP2M), UMR 7370, CNRS, Université Côte d'Azur, Nice, France.
- Saint Louis Régional Pharmacovigilance Centre, Clinical Investigation Centre (INSERM CIC 1427), Saint-Louis Hospital, Paris, 75010, France.
- Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
ORCID-Profile: Ioannis-Alexios Koumprentziotis
Zitieren
APA
Koumprentziotis, I. A., Cawley, A., Ewig, E., Gérard, A. O., Labat, M., Kamińska-Winciorek, G., Kubeczko, M., Rapparini, L., Starace, M., Grafanaki, K., Kamaratou, M., Mavroudis, D., Katoulis, A., Nikolaou, V., Heelan, K., & Koumaki, D. (2026). Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force “Dermatology for Cancer Patients” and pharmacovigilance analysis. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08090-5
Vancouver
Koumprentziotis IA, Cawley A, Ewig E, Gérard AO, Labat M, Kamińska-Winciorek G, et al. Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force “Dermatology for Cancer Patients” and pharmacovigilance analysis. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08090-5
BibTeX
@article{Koumprentziotis2026,
author = {Koumprentziotis, Ioannis-Alexios and Cawley, Alexander and Ewig, Elliot and Gérard, Alexandre O and Labat, Maëlys and Kamińska-Winciorek, Grażyna and Kubeczko, Marcin and Rapparini, Luca and Starace, Michela and Grafanaki, Katerina and Kamaratou, Maria and Mavroudis, Dimitrios and Katoulis, Alexander and Nikolaou, Vasiliki and Heelan, Kara and Koumaki, Dimitra},
title = {Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force “Dermatology for Cancer Patients” and pharmacovigilance analysis},
journal = {Breast Cancer Research and Treatment},
year = {2026},
doi = {10.1007/s10549-026-08090-5}
}
EUVIMED